If there is a schism among Big Pharma it is between those companies clinging on to the notion that pharma's future role is--as it is tod...

Yesterday the Dept. of Health and Human Services notified Vaxgen that since the biotech was in default of its $877 million contract to provi...

Genmab's fully human antibody HuMax-CD20 just took the title for the biggest single-product biopharma collaboration: up to $2.1 billion ...

Pfizer's decision to discontinue the development of it's HDL-boosting torcetrapib candidate/savior over the weekend leaves the Big P...

“Increased patient safety” drove Pfizer’s recent deal with UK wholesaler Alliance UniChem, according to the partners. But no one’s buying th...

Today Somaxon announced more positive results for its Phase III insomnia drug low-dose doxepin ( Silenor ). This trial--a test of the drug ...

Tool companies are popular among life-science VCs for their simplicity of exit: build a start-up around a truly novel technology, one of the...

What do Abgenix, Icos and Tanox have in common? Just as Eli Lilly decided it was better off buying Icos for the biotech's share of Ciali...

The news that torcetrapib, Pfizer's HDL-increasing CETP drug, slightly increases blood pressure is highly problematic for the world'...